linjc16/ctgov huggingface dataset:
Use of Predictive Model to Assist Patients Having an Embryo Transfer After IVF

Study Overview
=================
Brief Summary
-----------------
To determine in women undergoing IVF who are at high risk of multiple births (>35%), as calculated by the application of a predictive model - IVFsingleTM, if single embryo transfer will lead to both comparable clinical pregnancy rate (CPR) and other secondary outcomes such as live birth rate (LBR) and cumulative live birth rate (cLBR) in comparison to DET while reducing the incidence of multiple births (a secondary outcome measure).

Official Title
-----------------
The Application of a Validated Patient and Clinic Specific Predictive Model to Reduce the Incidence of Multiple Births Resulting From Fresh In Vitro Fertilization Cycles

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Under 38 1st or second IVF attempt - Exclusion Criteria: Over 37 years old donor egg third or greater IVF attempt cancellation in previous cycle for poor response successful pregnancy with IVF -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Control couples who will not use predictive model | |
| Predictive model<br>Couples who will use predictive model | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate at 8 -10 weeks gestational age |  | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Multiple pregnancy rate |  | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
predictive model, in vitro fertilization, elective single embryo transfer
BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Study Overview
=================
Brief Summary
-----------------
Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

Detailed Description
-----------------
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)

Official Title
-----------------
Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Age-related Macular Neovascular Degeneration

Conditions
-----------------
Macula Lutea Degeneration

Intervention / Treatment
-----------------
* Drug: intravitreal injection
* Drug: intravitreal injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Age-Related macular neovascularization degeneration Exclusion Criteria: other causes of macular neovascularization degeneration other macular diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: BEOVU<br>Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months | Drug: intravitreal injection<br>* Brolucizumab-Dbll intravitreal injection<br>* Other names: BEOVU;|
| Active Comparator: Eylea<br>Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months | Drug: intravitreal injection<br>* Aflipercept intravitreal injection<br>* Other names: Eylea;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best corrected visual acuity (BCVA) | Change in BCVA in LOG MARS(logarithm minimum angle of resolution | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
macular degeneration, BEOVU, Eylea
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period

Study Overview
=================
Brief Summary
-----------------
Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin

Official Title
-----------------
First REal-life Evaluation of Darifenacin in Overactive Bladder Patients During 3 Months

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Drug: Darifenacin (Emselex, BAY79-4998)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients > 18 years with symptoms of overactive bladder. Exclusion Criteria: Contraindications for the treatment with Darifenacin prolonged-release tablets according to the registered package insert. Pregnancy and lactation. Women of childbearing potential have to use an acceptable method of contraception. Concomitant treatment with drugs known to affect mainly the urinary bladder function (e.g. anticholinergics, antispasmodics) at any time during the study. Concomitant treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to Visit 1.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Darifenacin (Emselex, BAY79-4998)<br>* Patients in daily clinical treatment receiving Emselex according to local drug information<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate safety and tolerability of Darifenacin in the daily practice for the treatment of the OAB (Over Active Bladder) syndrome. |  | 3 months later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the patient's perception of bladder condition, the patient's use of the patient support program, the patient's and physician's assessment of treatment regarding efficacy and tolerability and patient's compliance with the treatment |  | 3 months later | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Overactive Bladder
Gait Stability of People With Lower-limb Amputations

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether there are quantifiable differences in walking stability, as measured by the acceleration of the trunk or the variation in step length, between people with unilateral below-knee amputations from vascular reasons or from trauma reasons.

Official Title
-----------------
Gait Stability of People With Lower-limb Amputations

Conditions
-----------------
Gait, Balance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be over the age of 18; be able to walk comfortably for a minimum of two (2) minutes; be willing to take part in the study, including signing the consent after carefully reading it; be able to read and understand English and follow verbal and visual instructions; are competent to give informed consent or have a proxy with power of attorney. have an unilateral, transtibial amputation; been fitted with a prosthesis for over six weeks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| vascular<br>People with a unilateral below-knee amputations due to a vascular reason | |
| nonvascular<br>People with a below-knee amputation due to nonvascular reasons | |
| Control<br>People with no gait impairments. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
amputees, lower limb
Resect and Discard Strategy in Clinical Practice

Study Overview
=================
Brief Summary
-----------------
Nowadays, post-polypectomy surveillance intervals are determined by combining endoscopic and pathologic data. Real-time imaging technologies, have shown promising results in discriminating adenomatous from non-adenomatous polyps. The resect and discard strategy for small polyps (based on real-time assessment of the histology and on the endoscopic resection without pathological examination) has been shown to be cost-effective in simulation models. No data exist about the impact of this strategy in clinical practice. The aim of present study was to assess whether the systematic use, in the everyday clinical practice, of the resect and discard strategy allows to correctly manage patients with small colonic polyps.

Conditions
-----------------
NBI, Endoscopic Assessment, Colonic Polyps, Endoscopic Surveillance

Intervention / Treatment
-----------------
* Other: endoscopic assessment of colonic polyps


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: consecutive adult outpatients undergoing colonoscopy for routine clinical indications Exclusion Criteria: surveillance interval was not necessarily directed by endoscopic findings (history of colorectal cancer, inflammatory bowel disease, hereditary polyposis syndromes, hereditary non-polyposis colorectal cancer) colonoscopy was performed without NBI technology at least one lesion > 10 mm or < 10 mm but with morphologic features suspect for malignancy (depressed or ulcerated lesions) was detected bowel preparation was inadequate caecal intubation was not accomplished polyps could not be resected for concomitant anticoagulation treatment, 7) polyps were resected but not retrieved for pathology.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| small polyps patients<br>Patients with one small polyps at colonoscopy | Other: endoscopic assessment of colonic polyps<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome of the study was to assess the agreement between endoscopy- and histology-determined surveillance strategies after small adenoma resection. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity of the endoscopic assessment (WL coupled with NBI) of small (<10 mm) adenomas |  |  | 
| operative characteristics for the diagnosis of diminutive (< 5 mm) adenomas |  |  | 
| the feasibility of non histologic evaluation, represented by the proportion of polyps in which a in-vivo diagnosis of adenoma can be made with high confidence |  |  | 
| specificity of the endoscopic assessment |  |  | 
| accuracy of the endoscopic assessment |  |  |
A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Study Overview
=================
Brief Summary
-----------------
The objectives were to collect information on vital status and pulmonary medication use at the predicted exit date for patients who participated in two one-year trials and withdrew prematurely. The primary objective was to ascertain the vital status (dead or alive) of these patients in the time interval between the patients' withdrawal from the trial and their predicted exit date (i.e: 48 weeks from first intake of randomised treatment + 30 days). The secondary objective was to collect information on classes of pulmonary medication and some other specified pulmonary interventions used by these prematurely discontinued patients at the time of their predicted exit date (i.e 48 weeks from the first intake of randomised treatment + 30 days) or at date of death (if this occurred during the time interval of interest, i.e 48 weeks from the first intake of randomised treatment + 30 days).

Official Title
-----------------
A Retrospective Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Either of Two One-Year Trials (205.254, 205.255) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Drug: Tiotropium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who withdrew prematurely from the randomised treatment phase of studies 205.254 and 205.255. Exclusion Criteria: Not applicable.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Premature withdrawal from tiotropium<br> | Drug: Tiotropium<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and status of patients dead or alive at the predicted end of treatment date |  | Until 48 weeks after first intake of randomised treatment + 30 days follow-up or date of death | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and specification of patients on pulmonary medications and other pulmonary interventions |  | Until 48 weeks after first intake of randomised treatment + 30 days follow-up or date of death |
Accuracy of the Pleth Variability Index to Predict Fluid Responsiveness in Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the accuracy of PVI (pleth variability index)

Detailed Description
-----------------
The aim of this study is to compare the accuracy of PVI (pleth variability index)with other hemodynamic variability that measured with PİCCO (SVV, PPV, CVP,CI)to predict the response of cardiac index to volume replacement in patients undergoing liver transplantation.

Official Title
-----------------
Accuracy and Utility of the Pleth Variability Index as a Predictor of Fluid Responsiveness During the Dissection and Anhepatic Phase of Liver Transplantation

Conditions
-----------------
Hemodynamic Instability

Intervention / Treatment
-----------------
* Device: PVI-guided fluid management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective living donor liver transplantation, >18 years patients Exclusion Criteria: Patients with: Arrhythmia Reduced left ventricular function (EF<40%) Hepatocellular carcinoma Pulmonary hypertension Fulminant liver failure valvular heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PVI<br>A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management. | Device: PVI-guided fluid management<br>* In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To test the ability of PVI to detect changes in preload during orthotopic liver transplantation | PVI is a measure of the dynamic changes in perfusion index that occur during a complete respiratory cycle | During dissection and anhepatic phase (3 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Elective living donor liver transplantation
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?

Study Overview
=================
Brief Summary
-----------------
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion. This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.

Official Title
-----------------
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission After 2 Cycles of Chemotherapy ?

Conditions
-----------------
Lymphoma, B-Cell

Intervention / Treatment
-----------------
* Procedure: Autograft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with High Risk Big B Cells Lymphoma Age > 18 years Exclusion Criteria: Not applicable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intensification treatment: Autograft<br> | Procedure: Autograft<br>* Autograft<br>|
| Standard chemotherapy (without autograft)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the survival without progress of transplanted patients versus not transplanted patients | Medical follow up | From the date of complete remission post C2 of chemotherapy up to 120 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cumulative Relapse Incidence | Medical follow up | From the date of complete remission post C2 of chemotherapy up to 120 months | 
| Overall survival | Medical follow up | From the date of complete remission post C2 of chemotherapy up to 120 months |
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel

Study Overview
=================
Brief Summary
-----------------
There are naturally occuring variations in the genetic makeup of all of us. Some of these variations may contribute to a change in susceptibility toward different diseases or change the prognosis. We are studying these genetic variations in patients with leukemia. The genes we are studying are those which influence detoxification of drugs and toxins.

Detailed Description
-----------------
We have prepared DNA on patients with leukemia (AML, CML and CLL) and we are studying the influence of polymorphisms in drug metabolism and disposition genes on predisposition and prognosis of these types of leukemia. The genes we are studying include: MDR1, CYP3A4, NQO1, NAT1/2, GST, hOCT. We plan to study other genes that may be contributory. Study includes comparing the frequency of polymorphisms in these genes with the frequency in the general population and the study of DNA biding proteins which bind at the sites of these polymorphisms.

Official Title
-----------------
Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel

Conditions
-----------------
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of acute myeloid leukemia or chronic lymphocytic leukemia Exclusion Criteria: under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
drug metabolism and disposition enzymes